Articles by Alison Bryant
Looks like Johnson & Johnson hit a roadblock in developing three experimental products the company acquired as part of its takeover of Dutch vaccine maker Crucell.
Novartis ($NVS) hit a key turning point with its vaccines division when a European Union committee backed the company's Bexsero meningitis shot.
An FDA panel dealt a blow to Dynavax Technologies on Thursday, raising concerns about the safety of the company's hepatitis B vaccine.
California's Dynavax Technologies scored a win when FDA staff said the company's Heplisav vaccine works against the contagious liver disease hepatitis B.
The World Health Organization deemed an inexpensive meningitis vaccine safe out of cold storage for four days, meaning health workers can more easily transport the drug to remote parts of Africa where meningitis A is common.
The global vaccines business is expected to grow by at least $30 billion over the next 5 years, and Takeda Pharmaceutical is hoping to get more skin in that game.
British health officials selected GlaxoSmithKline's Rotarix vaccine for the country's first routine rotavirus immunization program.
A GlaxoSmithKline malaria vaccine posted surprisingly lackluster results in a Phase III trial, putting a damper on solid results from previous studies. The vaccine against the mosquito-borne illness proved only 30% effective when given to African children in a clinical trial.
Italy lifted a ban on Novartis' flu vaccine several weeks after halting distribution due to small virus particles found in some injections.
After recalling 6 lots of an infant vaccine in Australia, GlaxoSmithKline ($GSK) is withdrawing another lot in Canada over concerns about potential microbial contamination.